Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
Gossamer Bio, led by former Receptos CEO Faheem Hasnain and CMO Sheila Gujrathi, revealed $100m in seed and Series A funding during a week in which 17 companies revealed VC rounds totaling $891.2m, giving them good news to discuss during the J.P. Morgan Healthcare conference.
You may also be interested in...
The company plans to release topline results this year in ulcerative colitis and pulmonary arterial hypertension. In UC, especially, Gossamer is aiming for an opportunity that remains untapped.
ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment.
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.